1. Building a pretreatment risk-stratification model for follicular lymphoma with genomic alterations and clinical parameters

Follicular lymphoma (FL) is a heterogeneous disease with variable outcome. Current pretreatment risk assessment methods focus on clinical parameters, such as the FL international prognostic index (FLIPI), FLIPI-2, PRIMA-PI, and PET. Although robust, these clinical scoring systems are limited in clinical utility and have not yet informed a precision approach to treatment. Integration of tumor gene mutations has been shown to improve FL prognosis with a clinicogenetic risk model, the m7-FLIPI score, which included the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), the FLIPI, and ECOG performance status.

Source: Cancer Genetics and Cytogenetics - March 31, 2019 Category: Genetics & Stem Cells Authors: Xiaoyu Qu, Hongli Li, Verena Passerini, Oliver Weigert, Michael LeBlanc, Jonathan W. Friedberg, Min Fang Source Type: research